The purpose of this study is to determine whether Magnetic Marker Monitoring is an appropriate opportunity to diagnose and to quantify a suspicious gastroparesis in subjects with diabetic polyneuropathy.

Inclusion Criteria:

• age > 50 years
• written informed consent
• Diabetes mellitus (only Diabetes mellitus group)
• Symptoms of diabetic gastroparesis with respect to nausea, postprandial fullness, abdominal pain, nausea, vomiting, abdominal bloating, early satiety, erratic blood glucose levels and weight loss evaluated by a standardized questionnaire (only Diabetes mellitus group)
• actually measured HbA1c (only Diabetes mellitus group)

Exclusion Criteria:

• Subject who is pregnant or breast feeding.
• Subject unwilling or unable to comply with study requirements.
• Any investigational agent or participation in another clinical trial within 28 days prior to randomization
• Any kind of disorder that compromises the ability of the subject to give written informed consent and/or comply with the study procedures.
• History of any medical condition that may increase the risks associated with study participation or may interfere with the interpretation of the study results.
• Known allergy to the investigational product, to any of its excipients
• Active inflammatory bowel disease, serious gastric ulceration or other bowel diseases like e.g. coeliac disease
• Implanted cardiac cardioverter-defibrillator or cardiac pacemaker
• Stenosis or stricture of gastrointestinal tract or any surgery in this region except for cholecystectomy or appendectomy
• Long-term medication with drug, that influence gastrointestinal motility (opiate, opioids, erythromycin, metoclopramide, laxatives) < 3 days before randomisation and before magnetic marker monitoring